Innovation Articles

1. Moving Beyond The mRNA Momentum: The Preclinical Path To Personalized Scalable Solid Tumor Immunotherapies 9/3/2026

   Translating early momentum into accessible, scalable therapies for refractory solid tumors requires prioritizing multitargeted off-the-shelf platforms at the preclinical stage.

2. The Future Of Cancer Drug Discovery Is Targeted Immune Activation 9/2/2026

   Using targeted delivery systems to generate therapeutic agents directly within tumors has implications for how oncology drugs are discovered and developed.

3. A Simple Eye Drop For A Blinding Disease? Claris Bio Raises $118M And Prepares For Pivotal Trials 9/1/2026

   CSB-001, Claris Bio’s eye drop for limbal stem cell deficiency, could offer a non-surgical way to improve vision, slow vision loss, and reshape LSCD care.

4. Emerging Fields In Immunology: New Frontiers For Therapeutic Discovery 9/1/2026

   Immunology has expanded into several specialized domains as our understanding of the immune system has grown.

5. Turning Pediatric Cancer Discoveries Into Medicines Requires Better Connections 8/27/2026

   Promising pediatric cancer science often stalls before patients benefit. David Adler explains how better connections could change that.

6. From Cell State Reprogramming To The Clinic: Turning The Regulatory Genome Into RNA Medicines (Pt. 2) 8/26/2026

   Ounzain discusses how regulatory genome biology is being translated into drug discovery, from identifying lncRNA targets to building clinically relevant therapeutics and more.

7. Novel Approach To Cancer Explores Severing Its Genetic Supply Line 8/25/2026

   Gene ablation represents an important and novel approach to treating cancer. One company is focusing on disabling the NRF2 gene to starve cancer cells.

8. Drugging The tRNA Control System 8/19/2026

   Drug discovery has usually treated transfer RNA as cellular infrastructure: indispensable, highly conserved, and therefore dangerous to perturb. That description is accurate but incomplete. 

9. Immune Reset In Rheumatology: Moving Beyond Disease Suppression Toward Durable Remission 8/18/2026

   EULAR 2026 highlighted growing momentum behind “immune reset,” an approach adapted from oncology that is quickly gaining traction in autoimmune rheumatic diseases.

10. What The China Biotech Debate Reveals About U.S. Drug Discovery 8/17/2026

    Peter Kolchinsky and Jason Kelly sparred over China’s biotech rise and what it means for U.S. drug discovery, investment, and strategic control.